-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
While all eyes are on Pfizer's COVID-19 vaccine research with BioNTech, a German biotech company, the big drugmaker has quietly "slimmed down" its research pipeline, eliminating two Phase 2 and one Phase 1 clinical trials.
, Pfizer announced its third-quarter financial cuts on October 27th, in line with quarterly practice.
The first phase of the study was the non-alcoholic fatty hepatitis 2 (NASH) drug PF-05221304, a candidate for acetyl coenzyme a carbohydrase inhibitor, which had previously been designated by the FDA as a fast-track and was undergoing a single-drug therapeutic clinical trial for patients with liver scarring.
not say why it was eliminated, except for filing under "Stopped Items."
PF-05221304 still appears to be active in trials used in a coalition with other drugs, but its future is likely to end up with major setbacks and failures, like most NASH drugs.
second mid-term asset to be phased out is arthritis candidate drug PF-06650833, an IRAK4 inhibitor, which Pfizer did not disclose further details about.
the end, the prostate cancer treatment vaccine PF-06753512, which is in clinical phase 1, has also been shelved, just as the fate of many other cancer vaccines has been met with promising scientific support, but has failed to meet expectations.
in addition to three research projects, Pfizer has stopped clinical research projects on four listed drugs since July 28 this year, including two Phase 3 trials in which CDK4/6 kinase inhibitor Ibrace (palbociclib) treats high-risk early-stage breast cancer and smoothened (SMO) antagonists Daurismo (glasdegib) in combination with cytosine and erythromycin to treat acute myeloid leukemia; a Phase 2 trial to study Daurismo's treatment of bone marrow growth abnormal syndrome; and a Phase 1 trial for the biological study of anti-PD-L1 monoantigen Bavencio (avelumab) for cancer.
the third quarter of this year, Pfizer had high hopes for a COVID vaccine program with BioNTech and was looking forward to releasing new data, but the big drugmaker is still waiting for results.
Pfizer had previously said it could release early data as early as late October to see if the vaccine candidates were effective and possibly seek approval.
but that deadline is about to pass.
But more positive changes can be found from the latest information released by Pfizer on the 27th, compared with the end of July this year, the company's total assets in the pipeline projects reached 92, including 58 new molecular entities (NMEs), 33 approved drugs additional adaptive research and 1 biosylikes, registration and approval projects increased by two, phase 1 clinical projects increased by four.
of these, six registered approved items were JAK1 inhibitor abrocitinib (PF-04965842) for the treatment of endemic dermatitis (prioritized and breakthrough therapy identified) (application for listing in the United States and the European Union); Chronic pain caused by arthritis (U.S. and European Union); Neulasta® biosimilar PF-06881894 treats leurial reduction in patients undergoing chemotherapy for cancer (EU); and androgen inhibitor Xtandi (enzalutamide) treats metastatic degenerative prostate cancer (EU); and Bavencio (avelumab) treats urethra cancer (EU).
In addition, Pfizer had four new approved adaptations in the third quarter of this year, namely BAVENCIO® (avelumab) in combination with platinum-containing chemotherapy for the first-line maintenance treatment of unrealized localized advanced or metastatic urethra cancer (approved in the United States®®); Adult patients with brafV600E mutated metastatic colorectal cancer treated throughout the body (EU approved); Hedgehog pathway inhibitor DAURISMOTM (glasdegib) was used in combination with low-dose LDAC to treat adult patients with acute myeloid leukemia (EU approved) who were not suitable for new diagnosis (first or secondary) of standard chemotherapy(EU approved); and Neulasta® (pegfilgrastim) biosimilar NYVEPRIATM (pegfilgrastim-apgf) to reduce infections caused by bone marrow-inhibiting anti-cancer drugs in patients with non-bone marrow malignancies, such as fever-neutral granulocytosis (approved in the United States).